You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Pudendal neuromodulation for incontinence and sphincter dyssynergia after spinal injury
SBC: Dignify Therapeutics LLC Topic: 106Spinal cord injurySCIfrequently produces severelife long bladder and bowel dysfunction that result in urinary and fecal incontinenceas well as sphincter dyssynergia that causes urinary retention and fecal impactionCurrent standard of care for incontinence consists of adult diaperswhile bladder and bowel voiding require multiple times daily catheterization of the bladder and regular digital extract ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
MARCKS: A novel therapeutic target in uveitis
SBC: BIOMARCK PHARMACEUTICALS, LTD Topic: NEIABSTRACT Uveitisthe most common form of intraocular inflammationaccounts forof preventable blindness in the USTreatment options are limited to cortiscosteroids and or immunosuppressantsbut both of these therapies show limited efficacy and are associated with numerous adverse and potentially serious side effectsNew therapeutic targets leading to effective and safe treatments are urgently requiredA ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Improving the Oral Bioavailability and In vivo Efficacy of a Novel TAK1 Inhibitor Targeting Rheumatoid Arthritis
SBC: EydisBio, Inc. Topic: NIAMSProject SummaryAbstract Rheumatoid arthritisRAis a chronic inflammatory disease in which hyperactivated immune cells induce maladaptive persistent inflammation in the jointsleading to synovial inflammation and bone remodelingIn the USRA currently affects roughlyof the population and carries a total annual societal cost burden of approximately $billionIn RAsustained elevations of pro inflammatory c ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Innovative 3D Printed Intravaginal Ring AnelleO-PRO, the first Single Administration of Progesterone for Infertility
SBC: Anelleo, Inc. Topic: NICHDInfertility is a global health problemand in the USmillion women are treated for infertility every yearThere is a strong need to promote patient friendly methods for progesterone supplementation in assisted reproductive technologyARTIntravaginal rings are well tolerated by womenare efficacious for contraception and hormone replacement therapyhave high patient complianceand are now in development f ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Novel High-Resolution Scintillation X-ray Detectors for Digital Dentistry
SBC: NGS Detectors LLC Topic: NIDCRProject SummaryNovel High Resolution Scintillation X ray Detectors for Digital Dentistry The transition from traditional film to digital X ray detectors has resulted in significant improvements across many areas for dental X ray imaging ranging from decreased wait timesimproved logistics and even lower radiation dose ratesOne significant drawback remains with digital X ray imaging howeverwhich is ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
A recombinant matrix to improve autologous tissue grafts
SBC: INSOMA BIO, INC. Topic: 102Abstract The objective of this proposal is to validate a new regenerative tissue matrix which studies to date indicate may be possible of redefining the limits of autologous fat graftingThis objective is motivated by the currently limited surgical options available to themillion patients undergoing reconstructive plastic surgery each year to treat body disfigurement and dysfunctionA core component ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Regenerative rotator cuff repair in a clinically relevant chronic disease model
SBC: Cytex Therapeutics, Inc. Topic: NIAMSABSTRACT Rotator cuff repairRCRis a common first line surgical solution to symptomatic rotator cuff injurywith overRCRs performed annuallyand growing at a rate ofUnfortunatelyof the cases are complicated by failure and re tear of the repaired tendonwhich commonly results in a significant reduction in activities of daily livingworkand or sports and recreation for the patient due to pain and restric ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Good Bowls: Empowering Communities to Achieve Good Food Access and Health Equity
SBC: Equiti Foods, LLC Topic: 102Abstract Emerging data indicate that those with pre-existing health conditions, such as obesity, diabetes, and heart disease, are at significantly increased risk of contracting COVID-19, as are low income and persons of color. Research also suggests that food insecurity (lack of access to affordable, nutritionally valuable food) and poor dietary intake are likely contributors to health disparities ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
A New Non-Invasive Approach for Accessing Pulmonary Arterial Stiffness in Patients with Pulmonary Hypertension
SBC: ARCUS-MED LLC Topic: NHLBIPulmonary hypertensionPHis a disease affecting approximatelyof the general population that is characterized by abnormally elevated mean pulmonary artery pressuremPAPand pulmonary vascular resistancePVRIf left untreatedPH can ultimately lead to right heart failure and deathCurrent diagnostic approaches utilize invasive right heart catheterizationRHCto measure mPAP and PVREarly detection of PH leads ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Development of a lead cyclic-PDZ-Enhancer drug for Anxiety and Depression
SBC: Aingeal, LLC Topic: 101Major depressive disorder is a debilitating mood disorder that affects ~7% of US adults in their lifetime, costing the U.S. economy more than $200 billion a year. Drugs that increase monoaminergic signaling are the mainstay of depression therapy, but have a delayed onset of action and are only effective in about 50% of affected patients. Aberrant brain-derived neurotrophic factor (BDNF) signaling ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health